Issue link: https://www.e-digitaleditions.com/i/1532011
Inhalation February 2025 21 A partner in innovative inhaled drug delivery Merxin Ltd: Your partner in innovative inhaled drug delivery. We design and supply inhaler devices, includ- ing MRX003 Capsule Dry Powder Inhaler (www. MRX003.com), MRX004 Soft Mist Inhaler (www. MRX004.com) and MRX006 Multidose Dose Dry Powder Inhaler (www.MRX006.com). As experts in inhaled drug delivery, we're committed to advancing respiratory healthcare. Our devices aren't just phar- maceutical devices. Featuring tested and trusted tech- nologies, they're your partners in pioneering new therapies and patient care. We make inhalers. We will launch you. Merxin Ltd. UK: +44 1553 403070 info@merxin.com www.merxin.com Comprehensive product support and analytical testing facilities Broughton offers comprehensive support for inhaled product development and analytical testing. Its expert team provides hands-on assistance through all stages, from early device selection to pre-clinical and clinical development. ey specialize in inhaled formulation systems and device compatibility, ensuring rigor- ous testing and data collection to meet regulatory requirements. Broughton's services include functional testing, performance benchmarking and device opti- mization for OINDPs (dry powder inhalers, pMDIs, SMIs and nasal sprays). With extensive experience in aerosol science and regulatory filings, Broughton delivers cost-effective, efficient testing solutions to help bring innovative inhalation products to market while ensuring quality and compliance. Broughton UK: +44 1756 700255 contact@broughton-group.com www.broughton-group.com pMDI technology and product development i2c Pharmaceutical Services is an experienced ser- vice provider for the development of pharmaceuti- cal formulations. Respitab is a propellant dispersible tablet that eliminates the need for complex mixing processes used in standard pMDI manufacturing. is patented, innovative platform enables transition to low global warming potential (GWP) pMDIs for a range of active pharmaceutical ingredients (APIs) and combination products. Respitab provides a cost- effective approach for new chemical entity (NCE) and generic pMDI products, simplifying manufac- turing processes for low GWP propellants. Respitab generates highly efficient aerosol properties and dose uniformity characteristics, reduces waste/API losses and facilitates scalability. i2c Pharma Services UK: +44 2920 757865 info@i2cpharm.co.uk www.i2cPharm.co.uk